Document is current
Any future updates will be listed below
-
Authors
Sayer, Matthew https://orcid.org/0000-0001-9618-2221
Webb, David J. https://orcid.org/0000-0003-0755-1756
Dhaun, Neeraj https://orcid.org/0000-0001-9128-6603
- License Information
-
More Information
Article History
Accepted: 22 January 2025
First Online: 7 February 2025
Competing interests
: D.J.W. has been involved in the development of ERAs over many years and was involved in the pivotal licensing study for aprocitentan as well as the first-in-human studies with zilebesiran, but did not receive personal funding for this work. D.J.W. has provided consultancy in the field of hypertension research for Johnson & Johnson, Nugerontix and Silence Therapeutics. The other authors declare no competing interests.
